{"transactions":[{"id":703503,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-24T21:26:12.000Z","date":"2026-07-22","kind":"sale","planned":false,"acquired":false,"shares":8111,"price":11.25,"value":91248.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price."}],"balance_after":148175,"source":{"system":"sec-edgar","filing":"0001193125-26-316279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526316279/ownership.xml","form_type":"4"}},{"id":715208,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:06.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":4677,"price":18,"value":84186.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025."}],"balance_after":156286,"source":{"system":"sec-edgar","filing":"0001821530-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000182153026000002/ownership.xml","form_type":"4"}},{"id":867100,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:17:34.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":87543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":87543,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":87543},"source":{"system":"sec-edgar","filing":"0001193125-26-088254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088254/ownership.xml","form_type":"4"}},{"id":867099,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:17:34.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":61280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":160963,"source":{"system":"sec-edgar","filing":"0001193125-26-088254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088254/ownership.xml","form_type":"4"}},{"id":944469,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T21:02:56.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":6379,"price":9.21,"value":58750.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":99683,"source":{"system":"sec-edgar","filing":"0001193125-26-006275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006275/ownership.xml","form_type":"4"}},{"id":1081393,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-25T20:05:06.000Z","date":"2025-07-23","kind":"sale","planned":false,"acquired":false,"shares":7462,"price":14.02,"value":104617.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":106062,"source":{"system":"sec-edgar","filing":"0000950170-25-098774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025098774/ownership.xml","form_type":"4"}},{"id":1228396,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:34:03.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":67429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":67429,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":67429},"source":{"system":"sec-edgar","filing":"0000950170-25-032192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032192/ownership.xml","form_type":"4"}},{"id":1228395,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:34:03.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":47200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":113524,"source":{"system":"sec-edgar","filing":"0000950170-25-032192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032192/ownership.xml","form_type":"4"}},{"id":1449353,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-24T20:17:08.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":96219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 22, 2024 with respect to shares of Common Stock, with 33% vesting on July 22, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":96219,"derivative":{"exercise_price":25.33,"expiration_date":"2034-07-21","underlying":"Common Stock","underlying_shares":96219},"source":{"system":"sec-edgar","filing":"0000950170-24-086061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024086061/ownership.xml","form_type":"4"}},{"id":1449352,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-24T20:17:08.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":66324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":66324,"source":{"system":"sec-edgar","filing":"0000950170-24-086061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024086061/ownership.xml","form_type":"4"}},{"id":1595466,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:24:31.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":2447,"price":7.77,"value":19013.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":101479,"source":{"system":"sec-edgar","filing":"0000950170-24-025992","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024025992/ownership.xml","form_type":"4"}},{"id":1661468,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:09:58.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":425000,"derivative":{"exercise_price":6.76,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0000950170-24-010485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024010485/ownership.xml","form_type":"4"}},{"id":1666434,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-30T21:01:19.000Z","date":"2024-01-29","kind":"sale","planned":true,"acquired":false,"shares":1849,"price":5,"value":9245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":103926,"source":{"system":"sec-edgar","filing":"0000950170-24-008803","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024008803/ownership.xml","form_type":"4"}},{"id":1681523,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:29:38.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":7028,"price":4.37,"value":30712.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":105775,"source":{"system":"sec-edgar","filing":"0000950170-24-003647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024003647/ownership.xml","form_type":"4"}},{"id":1692003,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-03T21:03:17.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":5182,"price":3.66,"value":18966.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":112803,"source":{"system":"sec-edgar","filing":"0000950170-24-000874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024000874/ownership.xml","form_type":"4"}},{"id":1704711,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-19T21:01:11.000Z","date":"2023-12-18","kind":"sale","planned":true,"acquired":false,"shares":1585,"price":3.5,"value":5547.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":117985,"source":{"system":"sec-edgar","filing":"0001209191-23-059103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123059103/doc4.xml","form_type":"4"}},{"id":1800660,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-21T20:02:44.000Z","date":"2023-08-18","kind":"sale","planned":false,"acquired":false,"shares":4718,"price":2.8,"value":13210.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $2.76 to $2.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":119570,"source":{"system":"sec-edgar","filing":"0001209191-23-046691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123046691/doc4.xml","form_type":"4"}},{"id":1833700,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-06T21:18:18.000Z","date":"2023-07-05","kind":"sale","planned":true,"acquired":false,"shares":5182,"price":4.83,"value":25029.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":124288,"source":{"system":"sec-edgar","filing":"0001209191-23-041607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123041607/doc4.xml","form_type":"4"}},{"id":2028298,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T21:15:19.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":425000,"derivative":{"exercise_price":6.77,"expiration_date":"2033-02-05","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001209191-23-007503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123007503/doc4.xml","form_type":"4"}},{"id":2056409,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-11T21:06:43.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":7331,"price":5.24,"value":38414.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":129470,"source":{"system":"sec-edgar","filing":"0001209191-23-002975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123002975/doc4.xml","form_type":"4"}},{"id":2178122,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-19T22:58:59.000Z","date":"2022-08-18","kind":"sale","acquired":false,"shares":432,"price":30.41,"value":13137.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":136801,"source":{"system":"sec-edgar","filing":"0001209191-22-046929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122046929/doc4.xml","form_type":"4"}},{"id":2178121,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-19T22:58:59.000Z","date":"2022-08-18","kind":"sale","acquired":false,"shares":4703,"price":29.75,"value":139914.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $29.29 to $30.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2."}],"balance_after":137233,"source":{"system":"sec-edgar","filing":"0001209191-22-046929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122046929/doc4.xml","form_type":"4"}},{"id":2423945,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-27T21:35:22.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":53058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date."}],"balance_after":53058,"derivative":{"exercise_price":39.87,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":53058},"source":{"system":"sec-edgar","filing":"0000899243-22-003443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924322003443/doc4.xml","form_type":"4"}},{"id":2423944,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-27T21:35:22.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":33302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date."}],"balance_after":141936,"source":{"system":"sec-edgar","filing":"0000899243-22-003443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924322003443/doc4.xml","form_type":"4"}},{"id":2435881,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-13T21:06:29.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":390,"price":49.16,"value":19172.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $48.83 to $49.31 per share."}],"balance_after":108634,"source":{"system":"sec-edgar","filing":"0001209191-22-003168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122003168/doc4.xml","form_type":"4"}},{"id":2435880,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-13T21:06:29.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":1380,"price":48.25,"value":66585.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $47.71 to $48.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3."}],"balance_after":109024,"source":{"system":"sec-edgar","filing":"0001209191-22-003168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122003168/doc4.xml","form_type":"4"}},{"id":2462355,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-21T21:08:47.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":14437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":128238,"derivative":{"exercise_price":35.52,"expiration_date":"2030-08-17","underlying":"Common Stock","underlying_shares":14437},"source":{"system":"sec-edgar","filing":"0001209191-21-070768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121070768/doc4.xml","form_type":"4"}},{"id":2462354,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-21T21:08:47.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":15977,"price":60,"value":958620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."}],"balance_after":110404,"source":{"system":"sec-edgar","filing":"0001209191-21-070768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121070768/doc4.xml","form_type":"4"}},{"id":2462353,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-21T21:08:47.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":14437,"price":35.52,"value":512802.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."}],"balance_after":126381,"source":{"system":"sec-edgar","filing":"0001209191-21-070768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121070768/doc4.xml","form_type":"4"}},{"id":2500629,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-22T22:41:03.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":59540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement."}],"balance_after":111944,"source":{"system":"sec-edgar","filing":"0001209191-21-066159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121066159/doc4.xml","form_type":"4"}},{"id":2555736,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-30T20:14:44.000Z","date":"2021-09-28","kind":"exercise","acquired":false,"shares":17325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":142675,"derivative":{"exercise_price":35.52,"expiration_date":"2030-08-17","underlying":"Common Stock","underlying_shares":17325},"source":{"system":"sec-edgar","filing":"0001209191-21-058176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121058176/doc4.xml","form_type":"4"}},{"id":2555735,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-30T20:14:44.000Z","date":"2021-09-28","kind":"sale","acquired":false,"shares":19460,"price":62.53,"value":1216833.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."}],"balance_after":52404,"source":{"system":"sec-edgar","filing":"0001209191-21-058176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121058176/doc4.xml","form_type":"4"}},{"id":2555734,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-30T20:14:44.000Z","date":"2021-09-28","kind":"exercise","acquired":true,"shares":17325,"price":35.52,"value":615384.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021."}],"balance_after":71864,"source":{"system":"sec-edgar","filing":"0001209191-21-058176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121058176/doc4.xml","form_type":"4"}},{"id":2594746,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T20:01:31.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":63,"price":90,"value":5670.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":54539,"source":{"system":"sec-edgar","filing":"0001209191-21-052742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121052742/doc4.xml","form_type":"4"}},{"id":2594745,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T20:01:31.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":1474,"price":88.65,"value":130670.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.47 to $89.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":54602,"source":{"system":"sec-edgar","filing":"0001209191-21-052742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121052742/doc4.xml","form_type":"4"}},{"id":2594744,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T20:01:31.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":1937,"price":87.9,"value":170262.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.42 to $88.33 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":56076,"source":{"system":"sec-edgar","filing":"0001209191-21-052742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121052742/doc4.xml","form_type":"4"}},{"id":2899091,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-22T23:18:49.000Z","date":"2021-01-20","kind":"grant","acquired":true,"shares":6851,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025."}],"balance_after":6851,"derivative":{"exercise_price":109.01,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":6851},"source":{"system":"sec-edgar","filing":"0001209191-21-004953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121004953/doc4.xml","form_type":"4"}},{"id":2899090,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2021-01-22T23:18:49.000Z","date":"2021-01-20","kind":"grant","acquired":true,"shares":18013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units (\"RSUs\") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025."}],"balance_after":58013,"source":{"system":"sec-edgar","filing":"0001209191-21-004953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121004953/doc4.xml","form_type":"4"}},{"id":3052216,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-19T20:12:16.000Z","date":"2020-08-17","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as to 25% of the underlying shares on the first anniversary of the grant date and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":160000,"derivative":{"exercise_price":35.52,"expiration_date":"2030-08-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-20-047483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919120047483/doc4.xml","form_type":"4"}},{"id":3052215,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-08-19T20:12:16.000Z","date":"2020-08-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exempt grant of restricted stock units pursuant to the Issuer's Inducement Equity Plan. The units will vest in four annual installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-20-047483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919120047483/doc4.xml","form_type":"4"}}]}